GlassScriptPhysician profile
John William Elliott
NPI 1508245226
$4,972.33
in general payments reported to CMS, 2019-2025
28 companies · $923 in 2025
The $923 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $394 · 2021: $812 · 2022: $879 · 2023: $866 · 2024: $764 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.76 |
| Education | $126.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $889.08 | 2020-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $771.49 | 2020-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $555.97 | 2020-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $473.73 | 2021-2025 | |
| Akebia Therapeutics INC | $304.71 | 2020-2024 | Auryxia, Vafseo |
| Amgen INC. | $277.39 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $275.26 | 2020-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $214.22 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $136.72 | 2021-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $124.08 | 2019 | |
| Aurinia Pharma U.S., INC. | $104.68 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $94.99 | 2019 | |
| Novo Nordisk INC | $88.19 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $81.51 | 2022-2023 | Benlysta |
| Daiichi Sankyo INC. | $75.91 | 2020-2024 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $71.60 | 2023-2025 | |
| Lilly USA, LLC | $70.64 | 2023-2025 | Jardiance |
| Nxstage Medical, INC. | $69.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.37 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $42.81 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $41.07 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $36.08 | 2023 | Oxlumo |
| Baxter Healthcare | $24.51 | 2024 | Renal - Acute |
| Medtronic, INC. | $21.83 | 2024 | Ellipsys Vascular Access System |
| Apellis Pharmaceuticals, INC. | $18.63 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $18.09 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.62 | 2022 | |
| Chiesi USA, INC. | $13.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.